Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.
Published By Datamonitor
|
22 Jul 2009 |
|
CommentWire
|
Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.
Published By Datamonitor
|
22 Jul 2009 |
|
CommentWire
|
Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.
Published By Datamonitor
|
29 Jul 2009 |
|
Expert View
|
Genzyme's plan to expand Clolar's label to include acute myeloid leukemia (AML) has been held up after an FDA advisory committee voted against its approval due to a lack of data. This news comes as a setback to Genzyme, and unless Clolar can show the desired efficacy among Genzyme's target patient population of elderly AML patients, further uptake of the drug in the clinical setting is unlikely.
Published By Datamonitor
|
03 Sep 2009 |
|
CommentWire
|
Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.
Published By Datamonitor
|
06 Nov 2009 |
|
CommentWire
|
Roche has announced that its Genentech unit has submitted two supplemental Biologics License Applications to the FDA for Avastin in the first-line treatment of metastatic HER-2-negative breast cancer. The regulator will most likely approve Avastin for these indications on the basis of progression-free survival extension results from Phase III clinical trial data.
Published By Datamonitor
|
18 Nov 2009 |
|
CommentWire
|
UCB's new rheumatoid arthritis drug, Cimzia, has been recommended for use on the NHS but only in conjunction with a company-sponsored patient access scheme. As such, UCB will cover all treatment costs for the first 12 weeks of therapy. This is a shrewd way of ensuring Cimzia's use by the cost-conscious NHS, and could herald change in both prescribing practices and future NICE submissions.
Published By Datamonitor
|
26 Jan 2010 |
|
CommentWire
|
A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.
Published By Datamonitor
|
01 Mar 2010 |
|
Expert View
|
Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.
Published By Datamonitor
|
30 Apr 2010 |
|
Expert View
|
The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.
Published By Datamonitor
|
18 May 2010 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.